Drug intelligence / Profile preview

BR113

Development stage: Phase 1
Lead developer: BioRay Pharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BR113 is an investigational **dual-payload antibody-drug conjugate** developed by BioRay for advanced solid tumors. It uses an anti-human trophoblast cell-surface antigen 2 antibody to deliver both a topoisomerase I inhibitor payload for tumor-cell killing and an immunostimulatory payload intended to enhance innate and systemic antitumor immune activity. BR113 has entered a multicenter, open-label, first-in-human Phase I monotherapy study in patients with advanced solid tumors. ([aacrjournals.org](https://aacrjournals.org/cancerres/article/84/6_Supplement/3132/735456/Abstract-3132-A-novel-dual-drug-antibody-drug))

Targets

TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on BR113.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR113.

Explore the full profile